Mukka Proteins Completes Acquisition, Ento Proteins Becomes Wholly Owned Subsidiary
Mukka Proteins acquired 1,000 equity shares of Ento Proteins Private Limited for ₹32.30 lakh, making it a wholly-owned subsidiary. EPPL reported FY25 turnover of ₹7.46 crore and PAT of ₹49.47 lakh. This acquisition supports Mukka's alternate proteins business expansion.
The acquisition is strategic for business expansion, but the relatively small financial value of the transaction (₹32.30 lakh) limits the immediate impact to medium.
The acquisition of Ento Proteins Private Limited and its subsequent status as a wholly-owned subsidiary is a positive strategic move for Mukka Proteins, aligning with its business expansion plans.
Mukka Proteins Limited has successfully completed the acquisition of 1,000 equity shares of Ento Proteins Private Limited (EPPL) for a total consideration of ₹32,30,000. This strategic move, finalized on February 23, 2026, makes EPPL a wholly-owned subsidiary of Mukka Proteins.
EPPL, incorporated on March 8, 2021, is engaged in the manufacturing of insect meal and insect oil. For the financial year 2024-25, EPPL reported a turnover of ₹7,46,27,305 and a Profit After Tax (PAT) of ₹49,47,474. The acquisition aligns with Mukka Proteins' strategic plans to expand its alternate proteins business.
The company confirmed that the investment was made on an arm's length basis, although EPPL is considered a related party due to its subsidiary status. No specific governmental or regulatory approvals were required for this acquisition.
What to do with a filing like this
Mukka Proteins Limited filed this with the NSE as a statutory disclosure, categorised under acquisition. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Mukka Proteins Limited. Read the original for the full detail.